TABLE 4.
Results of network meta-analysis of different Chinese patent medicines combined with letrozole in the treatment of ovulation disorders.
| Ovulation rate | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| KT + LE | |||||||||
| 3.185 (0.7724, 9.7730) | ZZ + LE | ||||||||
| 43.050 (1.1800, 212.10) | 19.3000 (0.3382, 93.360) | XJ + LE | |||||||
| 0.8054 (0.0990, 3.1900) | 0.3585 (0.0281, 1.5770) | 0.1520 (0.0019, 0.8321) | YY + LE | ||||||
| 1.1670 (0.4391, 2.5550) | 0.5175 (0.1018, 1.4970) | 0.2197 (0.0049, 0.9483) | 2.9500 (0.3124, 11.190) | DK + LE | |||||
| 0.2858 (0.1580, 0.4700) | 0.1267 (0.0312, 0.3111) | 0.0540 (0.0014, 0.2164) | 0.7232 (0.0928, 2.5160) | 0.2772 (0.1289,0.5121) | LE | ||||
| Pregnancy Rate | |||||||||
| KT + LE | |||||||||
| 0.8738 (0.4091, 1.659) | ZZ + LE | ||||||||
| 0.7115 (0.1755, 2.0040) | 0.9039 (0.1886, 2.7570) | YY + LE | |||||||
| 1.6670 (0.8427, 3.0010) | 2.1190 (0.8246, 4.5030) | 3.3800 (0.7190, 9.961) | DK + LE | ||||||
| 0.4131 (0.3048, 0.5471) | 0.5252 (0.2623, 0.9342) | 0.8370 (0.2108, 2.2490) | 0.2693 (0.1454, 0.4514) | LE | |||||
| Endometrial Thickness on the Follicular Maturity Day | |||||||||
| KT + LE | |||||||||
| 0.0385 (−2.2780, 2.391) | ZZ + LE | ||||||||
| −1.0940 (−2.747, 0.5871) | −1.1330 (−3.8560, 1.5800) | XJ + LE | |||||||
| 1.1100 (−1.2340, 3.4920) | 1.0720 (−2.1140, 4.2830) | 2.2040 (−0.5356, 4.9510) | BL + LE | ||||||
| 0.6452 (−0.7600, 2.0890) | 0.6067 (−1.9830, 3.2090) | 1.7390 (−0.2594, 3.7510) | −0.4649 (−3.073, 2.151) | DK + LE | |||||
| 2.2720 (1.661, 2.9160) | 2.2340 (−0.0146, 4.4850) | 3.3660 (1.8270, 4.9150) | 1.1620 (−1.1200,3.437) | 1.6270 (0.3441, 2.9080) | LE | ||||